程序性死亡受体-1/程序性死亡受体配体-1抑制剂在胃癌免疫治疗中的研究进展

Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Gastric Cancer

胃癌是一种消化道恶性肿瘤,虽然手术、放疗及化疗延长了晚期胃癌(GC)患者的生存期,但预后仍然很差。近年来,随着以免疫检查点抑制剂(ICIs)为代表的免疫疗法在实体肿瘤治疗中获得的重大突破,癌症治疗模式已经被重塑。目前研究最多的ICIs是程序性死亡受体-1(PD-1)、程序性死亡受体配体-1(PD-L1)抑制剂。本文总结了PD-1抑制剂、PD-L1抑制剂在GC中的当前试验及最新数据,并讨论了其目前的局限性。

Gastric cancer(GC)is a malignant tumor of digestive tract.Despite the progress of surgery,radiotherapy and chemotherapy,the prognosis of gastric cancer is still very poor.In recent years,with the major breakthrough of immunotherapy represented by immune checkpoint inhibitors(ICIs)in the treatment of solid tumors,the cancer treatment model has been reshaped.At present,the most studied ICIs are programmed cell death-1(PD-1)and programmed cell death ligand-1(PD-L1)inhibitors.In this review,we summarize the current trials and latest data of PD-1 inhibitors and PD-L1 inhibitors in GC,and discuss their current limitations.